DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsAugust, 31 20258 390 660Gross total of voting rights : 12 705 441Net total* of voting rights ...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsJuly, 31 20258 390 660Gross total of voting rights : 12 705 786Net total* of voting rights : ...

Key Takeaways Halozyme offers a discounted PEG and 31% expected growth, backed by its ENHANZE drug delivery tech.Phibro shows discounted PEG and P/E with a 15% long-term growth rate in animal health and nutrition.Leidos and PDD both present low PEG ratios, with growth rates of 14.6% and 9.7%, respectively.In the equity market, investments need to be prudently hedged to overcome uncertainties and limit losses related to external shocks. A question that often arises is whether one should resort to a value str ...

Zoetis Inc. ( ZTS ) is a global market leader in pet and livestock health products with an excellent growth profile and outlook. The dividend safety is rock-solid, and the firm systematically returns cash to shareholdersI am a self-taught individual investor and I have been investing in stocks for over 25 years. I focus on dividend growth investing with a long-term horizon since I believe in the compounding power of dividend growth investing. I generally look for undervalued large cap stocks with sustainabl ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2025 Earnings Conference August 28, 2025 9:00 AM ET Company Participants Daniel M. Bendheim - Executive VP of Corporate Strategy & Director Glenn C. David - Chief Financial Officer Jack Clifford Bendheim - Chairman, President & CEO Larry L. Miller - Chief Operating Officer Conference Call Participants Ekaterina V. Knyazkova - JPMorgan Chase & Co, Research Division Erin Elizabeth Wilson Wright - Morgan Stanley, Research Division Michael Leonidovich Ryskin - B ...

Core Insights - Phibro Animal Health (PAHC) reported adjusted earnings per share (EPS) of 57 cents for Q4 fiscal 2025, an increase from 41 cents in the same quarter last year, surpassing the Zacks Consensus Estimate by 9.62% [1] - The company achieved full-year adjusted EPS of $2.09, reflecting a 75.6% increase from fiscal 2024, also exceeding the Zacks Consensus Estimate by 2.45% [1] Revenue Performance - PAHC's net sales for Q4 reached $378.7 million, a 38.6% increase year-over-year, and exceeded the Zacks Consensus Estimate by 4.86% [2] - For fiscal 2025, total net sales were reported at $1.30 billion, up 27.4% from the previous year, beating the Zacks Consensus Estimate by 1.56% [2] Segment Analysis - In Q4, the Animal Health segment's net sales rose 53% to $292.5 million, outperforming the projected $264.4 million [3] - Within Animal Health, medicated feed additives (MFAs) and others saw a 77% year-over-year growth, driven by $94.5 million in revenues from the Zoetis MFA portfolio [4] - Nutritional specialty product sales increased by 11%, while net vaccine sales grew by 21% due to rising demand in Latin America [4] - The Mineral Nutrition segment's net sales increased by 3% to $64.2 million, falling short of the forecast [5] - Performance Products segment sales rose 13% to $22.1 million, exceeding expectations [5] Margin and Profitability - Gross profit for Q4 increased by 26.2% year-over-year to $110 million, although gross margin contracted by 287 basis points to 29.1% due to a 44.5% rise in the cost of goods sold [6] - Operating profit rose 82.2% year-over-year to $33.7 million, with the operating margin expanding by 213 basis points to 8.9% [6] Future Guidance - For fiscal 2026, PAHC anticipates net sales between $1.43 billion and $1.48 billion, indicating a 12% growth, with adjusted EPS expected in the range of $2.52 to $2.70, representing a 25% increase [9] - The Zacks Consensus Estimate for fiscal 2026 net sales is $1.41 billion, while the adjusted EPS consensus stands at $2.30 [9] Overall Assessment - PAHC concluded Q4 on a strong note, with earnings and revenues exceeding estimates, driven by robust performance in the Animal Health portfolio [10] - The company’s fiscal 2026 guidance reflects confidence in its growth trajectory, supported by strong portfolio performance and disciplined execution [10]

Financial Performance - Consolidated - Q4 Net Sales increased by 39% to $378.7 million compared to $273.2 million in FY24[13] - Q4 Adjusted EBITDA increased by 49% to $50.0 million compared to $33.4 million in FY24[13] - Full Year Net Sales increased by 27% to $1,296.2 million compared to $1,017.7 million in FY24[16] - Full Year Adjusted EBITDA increased by 65% to $183.7 million compared to $111.2 million in FY24[16] Financial Performance - Animal Health - Q4 Animal Health Net Sales increased by 53% to $292.5 million[11,19] - Q4 Legacy Animal Health Net Sales increased by 3% to $197.9 million[11,19] - Full Year Animal Health Net Sales increased by 36% to $962.8 million[11,22] - Full Year Legacy Animal Health Net Sales increased by 7% to $754.6 million[11,22] Financial Guidance - Fiscal Year 2026 - The company projects Net Sales between $1.425 billion and $1.475 billion[12] - The company projects Adjusted EBITDA between $225 million and $235 million[12]

Key Takeaways Phibro Animal Health (PAHC) shares climbed 76.4% in a year, showcasing impressive momentum. The stock has outpaced the industry's 4.9% growth and the S&P 500 Composite's 16% gain. With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment. Phibro shares jumped 76.4% in a year, beating industry and S&P 500 growth. PAHC's revenue gains came from Mineral Nutrition and Performance Products. PAHC's ...

Core Points - The board of directors of Virbac has approved the compensation terms for Paul Martingell as CEO, which will be submitted for shareholder approval [1] Fixed Compensation - Paul Martingell's gross annual fixed compensation is set at €600,000, including other remuneration related to his mandates within the Virbac group [2] - For 2025, the fixed compensation will be prorated based on his effective presence from September 1, 2025, to December 31, 2025 [2] Short-term Variable Compensation - The short-term variable compensation will be determined based on the achievement of objectives, measured by the board during the first quarter of the following fiscal year after the approval of annual financial statements [3] Long-term Incentive (LTI) Compensation - Paul Martingell will receive 1,000 performance shares under the performance share plan established on March 12, 2025 [4] - Future performance share plans may award him shares equivalent to his gross annual fixed compensation, capped at 1,500 performance shares [5] Exceptional Compensation: Onboarding Bonus - To compensate for lost benefits from his previous role, Martingell will receive 2,000 performance shares after two years, contingent on achieving an Ebit adjusted greater than 10% [6] - An additional 1,000 performance shares will be granted after three years under the same Ebit condition [7] - A welcome bonus of €500,000 gross in cash will be paid in two installments [9] Other Compensation Elements and Benefits - Martingell will benefit from French social security, healthcare, and retirement schemes [12] - He will have private unemployment insurance fully covered by the company [13] - A company car will be provided as a benefit in kind [14] - Relocation costs to the Nice region will be covered, including a furnished rental for four months, capped at €2,000 per month [15] Non-compete Agreement and Indemnity - Martingell will be subject to a non-compete clause for 18 months post-cessation of his role, with an indemnity of 80% of his gross monthly fixed compensation during this period, capped at €600,000 [16][18][19]

Financial Data and Key Metrics Changes - The company reported revenues of $298,000, representing a 141% increase compared to the same quarter last year [6][4] - Gross profit totaled $187,000, which is 63% of revenues, marking a 69% increase from $111,000 in the same quarter last year [7] - Operating loss decreased by 10% to $1,800,000 compared to the same quarter a year ago [8] - Net loss available to common stockholders was $2,300,000, or a negative loss of $0.09 per share, which is a 15% improvement from the previous year's net loss of $2,000,000 [8] - Available cash increased to $3,300,000 from $220,000 as of March 31, 2025 [9] - Total liabilities decreased by 39% to $1,200,000 during the quarter [9] Business Line Data and Key Metrics Changes - The U.S. National distributor network increased sales by 192% year-over-year, contributing $198,000 or 67% of total revenue [4][6] - The introduction of the new Precise PRP product alongside Spring contributed to the revenue increase [6] Market Data and Key Metrics Changes - The Mexican veterinary health care market is projected to grow at a compounded annual growth rate of 11%, reaching $2.4 billion by February 2031 [3] - The U.S. animal health market is expected to double to $11.3 billion by February 2030, providing significant growth opportunities [24] Company Strategy and Development Direction - The company is focused on expanding the adoption of its flagship product, Spring, and increasing awareness of Precise PRP for treating osteoarthritis in animals [12] - Strategic partnerships have been formed, including collaborations with Commonwealth Markets and Piezo BioMembrane, to enhance product offerings and market reach [20][22] - The company is integrating AI technology with its veterinary products to create a global pet care ecosystem [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for fiscal 2026 and beyond [24] - The company believes it is well-positioned to accelerate growth and expand into high-growth markets [24] Other Important Information - The company has recently qualified to trade on the OTCQX best market, enhancing visibility and liquidity for investors [11] - The commercialization of Spring and Precise PRP has received favorable feedback from veterinarians regarding their effectiveness [14] Q&A Session Summary - No questions were raised during the Q&A session, leading to the conclusion of the call [29][33]